Nonalcoholic steatohepatitis and obesity as one of the main predictors of metabolic syndrome development in children and adolescents

O.Yu. Belousova

Abstract


This article deals with the importance of isolating the metabolic syndrome in pediatric gastroenterological practice, since almost all the major components of the metabolic syndrome are already found in childhood. In addition, this condition diagnosed at early stages of the disease development is theoretically reversible, that is with the prescription of an adequate treatment, it is possible to reduce the severity of its main manifestations and to prevent diabetes mellitus type 2, dyslipidemia and cardiovascular diseases. The main predictors of the development of this pathology are obesity, whose growth tends to increase constantly, and non-alcoholic steatohepatitis, often manifested in adolescence. The advisability of using drugs that affect hepatic metabolism and are able to exert a lipid-regulating effects, in particular, essential phospholipids, is discussed.

Keywords


metabolic syndrome; obesity; non-alcoholic steatohepatitis; childhood and adolescence; fatty liver disease; essential phospholipids; review

References


American Diabetes Association. Standards of medical care in diabetes — 2011. Diabetes Care. 2011;34 (supp l1):S11-S61. doi: 10.2337/dc11-0262.

WHO Regional Office for Europe. Country profiles on nutrition, physical activity and obesity in the 53 WHO European Region Member States. Methodology and summary. / World Health Organization; 2013. UN City, Marmorvej 51, DK-2100 Copenhagen O, Denmark. 12 р. Available from: http://www.euro.who.int/en/publications/abstracts/country-profiles-on-nutrition,-physical-activity-and-obesity-in-the-53-who-european-region-member-states.-methodology-and-summary-2013

Jolliffe CJ, Janssen I. Development of age-specific metabolic syndrome criteria that are linked to the Adult Treatment Panel III and International Diabetes Federation Criteria. J Am Coll Cardiol. 2007;49:891-8. doi: 10.1016/j.jacc.2006.08.065.

Abaturov AE. Gastroenterological aspects of metabolic syndrome in childhood. Zdorov'e Ukrainy.2012;3(22):13-5. (In Russian).

Zimmet P, Alberti KG, Kaufman F, Tajima N, Silink M, Arslanian S, Wong G, Bennett P, Shaw J, Caprio S. The metabolic syndrome in children and adolescents — an IDF consensus report. IDF Consensus Group. Pediatr Diabetes. 2007 Oct;8(5):299-306. PMID:17850473. doi: 10.1111/j.1399-5448.2007.00271.x.

Gundermann KJ, Kuenker A, Kuntz E, Droździk M. Activity of essential phospholipids (EPL) from soybean in liver diseases. Pharmacol. Rep. 2011;63;3:643-59. PMID: 21857075. doi: 10.1016/S1734-1140(11)70576-X12.

Belousov JuV. Dysfunction of the biliary system in children. Zdorov'e Ukrainy. 2015 Mar;12-4. (In Russian).

Balukova EV, Tkachenko EI, Uspenskij JuP. Metabolicheskij sindrom pri zabolevanijah pecheni [The metabolic Syndrome in liver diseases]. Lectures for the gastroenterologist. Part 2: Symptoms and syndromes in clinical practice. Collection of articles. Donetsk; 2009. 82-90. (In Russian).

Grinevich VB, Mehtiev SN. Kliniko-morfologicheskaja diagnostika hronicheskih zabolevanij pecheni v sochetanii s patologiej serdechno-sosudistoj sistemy: metodicheskie rekomendacii [Clinical and morphological diagnosis of chronic liver diseases combined with cardiovascular pathology: Textbook. Main Military Medical Administration, Military Medical Academy. Saint-Petersburg; 2000. 25 p. (In Russian).

EASL Recommendations on Treatment of Hepatitis C 2016, Guidelines. Journal of Hepatology. 2017;66(1):153-94. PMID: 27667367. doi: 10.1016/j.jhep.2016.09.001.

Yang M, Gong S, Ye SQ, et al. Non-alcoholic fatty liver disease in children: focus on nutritional interventions. Nutrients. 2014;6(11):4691-705. PMID: 25353664. doi: 10.3390/nu6114691.

Partha P, Sayantan R. Alcoholic liver disease: a comprehensive review. EMJ. 2016;1(2):85-92.

Zaremba YH, Zaremba-Fedchyshyn OV, Zaremba OV, Gazda MM, Fedchyshyn NR, Golyk OM, Prokosa MI, Shevchun OM. Liver function, uric acid levels and blood lipid profile in combined lipid-lowering therapy of patients with cardiovascular diseases . Semejnaja medicina. 2013;2(46):109-11. (In Ukrainian).

Ng M, Fleming T, Robinson M, et al. Global, regional, and national prevalence of overweight and obesity in children and adults during 1980-2013: A systematic analysis for the Global Burden of Disease Study 2013. Lancet. 2014 Aug;384:766-81. doi: 10.1016/S0140-6736(14)60460-8.

Chalasani N, Younossi Z, Lavine JE, Diehl AM, Brunt EM, Cusi K, Charlton M, Sanyal AJ. Practice Guidelines. The Diagnosis and Management of Non-alcoholic Fatty Liver Disease: Practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Am J Gastroenterol. 2012 Jun;107:811-26. PMID: 22641309. doi: 10.1038/ajg.2012.128.

Babak OJa, Prosolenko KA, Babak MO, Kurinnaja EG, Sytnik KA. Application of a new drug influencing endocannabinoid system in treatment of comorbid gastroenterological pathology. International Medical Journal. 2014;2:33-7.

Kidd P. Phosphatidylcholine: a superior protectant against liver damage. Alt Med Rev. 1996;1(4):258-74.

Gundermann KJ, Gundermann S, Drozdzik M, Mohan Prasad VG. Essential phospholipids in fatty liver: a scientific update. Clin Exp Gastroenterol. 2016 May;9:105-17. PMID: 27217791. doi: 10.2147/CEG.S96362.

StepanovJu.M. The use of essential phospholipids for the treatment of fatty liver disease. Gastrojenterologija. 2016;4(62):58-64.: doi: 10.22141/2308-2097.4.62.2016.81089. (In Russian).

Sas E, Grinevich V, Efimov O, Shcherbina N. Beneficial influence of polyunsaturated Phosphatidylcholine enhances functional liver condition and liver structure in patients with Nonalcoholic steatohepatitis accompanied by diabetes type 2. Results of prolonged randomized blinded prospective clinical study. Journal of Hepatology 2013;58:S549. doi: 10.1016/S0168-8278(13)61365-3.

Fadeenko GD. Non-alcoholic fatty liver disease: modern approaches to treatment. Zdorov'e Ukrainy. 2016; 4(42):29.

HarchenkoNV, FadeenkoGD, KochuevaMN. Hepatoprotectors in the treatment of comorbid pathology: features of use. Zdorov'e Ukrainy. 2016;4(42):16-7.

Halfon Neal, Verhoef Philip A., Kuo Alice A. Childhood Antecedents to Adult Cardiovascular Disease. Pediatrics. 2012;33(2):51-61. PMID: 22301031. doi: 10.1542/pir.33-2-51.




DOI: https://doi.org/10.22141/2224-0551.12.2.1.2017.100990

Refbacks

  • There are currently no refbacks.


Copyright (c) 2017 CHILD`S HEALTH

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

 

© Publishing House Zaslavsky, 1997-2017

 

 Яндекс.МетрикаSeo анализ сайта Рейтинг@Mail.ru